EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial

Rawad A Yared, Chieh-Chang Chen, Astrid Vandorpe, Marianna Arvanitakis, Myriam Delhaye, Michael Fernandez Y Viesca, Vincent Huberty, Daniel Blero, Emmanuel Toussaint, Axel Hittelet, Didier Verset, Walter Margos und 5 weitere

Pancreatology · 2024

DOI: 10.1016/j.pan.2024.02.009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pancreatology, 2024. Verfasst von Rawad A Yared und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatopancreatology, Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Université Libre de Bruxelles, …. Hauptthemen laut MEDLINE: Cholangiopancreatography, Endoscopic Retrograde, Pancreatitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AOP Orphan Pharmaceuticals GmbH, Fonds Erasme, Fonds De La Recherche Scientifique - FNRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Hemin, a heme oxygenase 1 activator has shown efficacy in the prevention and treatment of acute pancreatitis in mouse models. We conducted a randomized controlled trial (RCT) to assess the protective effect of Hemin administration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in patients at risk. METHODS: In this multicenter, multinational, placebo-controlled, double-blind RCT, we assigned patients at risk for PEP to receive a single intravenous dose of Hemin (4 mg/kg) or placebo immediately after ERCP. Patients were considered to be at risk on the basis of validated patient- and/or procedure-related risk factors. Neither rectal NSAIDs nor pancreatic stent insertion were allowed in randomized patients. The primary outcome was the incidence of PEP. Secondary outcomes included lipase elevation, mortality, safety, and length of stay. RESULTS: A total of 282 of the 294 randomized patients had complete follow-up. Groups were similar in terms of clinical, laboratory, and technical risk factors for PEP. PEP occurred in 16 of 142 patients (11.3%) in the Hemin group and in 20 of 140 patients (14.3%) in the placebo group (p = 0.48). Incidence of severe PEP reached 0.7% and 4.3% in the Hemin and placebo groups, respectively (p = 0.07). Significant lipase elevation after ERCP did not differ between groups. Length of hospital stay, mortality and severe adverse events rates were similar between groups. CONCLUSION: We failed to detect large improvements in PEP rate among participants at risk for PEP who received IV hemin immediately after the procedure compared to placebo. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number, NCT01855841).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangiopancreatography, Endoscopic RetrogradePancreatitisAnimalsHumansMiceAnti-Inflammatory Agents, Non-SteroidalHeme Oxygenase-1HeminLipaseAdministration, Intravenous

Stichwörter der Autor:innen

Cytoprotective effectERCPHeme oxygenaseHeminPost-ERCP pancreatitis

Substanzen

Anti-Inflammatory Agents, Non-SteroidalHeme Oxygenase-1HeminLipase

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatopancreatology, Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. Electronic address: rawa…
  • Department of Internal Medicine, National Taiwan University Hospital, Taiwan.
  • Pharmacy, Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Université Libre de Bruxelles (ULB) Brussels, Belgium.
  • Department of Gastroenterology and Hepatopancreatology, Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.
  • Department of Gastroenterology and Hepatopancreatology, Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium; Department of Gastroente…
  • Department of Gastroenterology, CHU Charleroi, Charleroi, Belgium; CHU Brugmann, Department of Gastroenterology, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Förderung

  • AOP Orphan Pharmaceuticals GmbH
  • Fonds Erasme
  • Fonds De La Recherche Scientifique - FNRS

Zitieren

APA

Yared, R. A., Chen, C. C., Vandorpe, A., Arvanitakis, M., Delhaye, M., Viesca, M. F. Y., Huberty, V., Blero, D., Toussaint, E., Hittelet, A., Verset, D., Margos, W., Le Moine, O., Njimi, H., Liao, W. C., Devière, J., & Lemmers, A. (2024). Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial. Pancreatology. https://doi.org/10.1016/j.pan.2024.02.009

Vancouver

Yared RA, Chen CC, Vandorpe A, Arvanitakis M, Delhaye M, Viesca MFY, et al. Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial. Pancreatology. 2024. doi:10.1016/j.pan.2024.02.009

BibTeX
@article{Yared2024,
  author = {Yared, Rawad A and Chen, Chieh-Chang and Vandorpe, Astrid and Arvanitakis, Marianna and Delhaye, Myriam and Viesca, Michael Fernandez Y and Huberty, Vincent and Blero, Daniel and Toussaint, Emmanuel and Hittelet, Axel and Verset, Didier and Margos, Walter and Le Moine, Olivier and Njimi, Hassane and Liao, Wei-Chih and Devière, Jacques and Lemmers, Arnaud},
  title = {Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial},
  journal = {Pancreatology},
  year = {2024},
  doi = {10.1016/j.pan.2024.02.009}
}
Kostenlos starten →